Evidence map›Paper›PMID 42667548›Full record

ReviewJournal of cancer survivorship : research and practice2026

Fertility in breast cancer survivorship: a scoping review.

Sanjna Rajput, Elizabeth J Cathcart-Rake, Kathryn J Ruddy, Chandra C Paff Shenoy, Christine Connors, Dame Idossa

Abstract readReview
PubMed Publisher
In one paragraph

Review in Journal of cancer survivorship : research and practice, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Sanjna RajputMayo Clinic School of Graduate Medical Education, Internal Medicine Residency, Mayo Clinic, Rochester, MN, USA.
Elizabeth J Cathcart-RakeDepartment of Oncology, Mayo Clinic, 200 First Street SW, Rochester, MN, 55905, USA.
Kathryn J RuddyDepartment of Oncology, Mayo Clinic, 200 First Street SW, Rochester, MN, 55905, USA.
Chandra C Paff ShenoyDivision of Reproductive Endocrinology and Infertility, Department of Obstetrics and Gynecology, Mayo Clinic, Rochester, MN, USA.
Christine ConnorsDepartment of Oncology, Mayo Clinic, 200 First Street SW, Rochester, MN, 55905, USA.
Dame IdossaDepartment of Oncology, Mayo Clinic, 200 First Street SW, Rochester, MN, 55905, USA. idossa.dame@mayo.edu.ORCID http://orcid.org/0000-0003-1861-3553

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeTo summarize current evidence on fertility issues in breast cancer survivors, including gonadotoxic potential of cancer-directed therapies, available fertility preservation options, counseling practices, post-treatment pregnancy outcomes, and future research needs. This review aims to guide clinical practice and to highlight current gaps in oncofertility care.

methodsA critical review of recent literature was conducted, consolidating data from clinical trials, cohort studies, guidelines, and expert consensus. Key themes in oncofertility care for breast cancer survivors were mapped through the breadth of literature, including therapy-associated gonadotoxicity, fertility preservation strategies, multidisciplinary care models, and post-treatment reproductive outcomes.

resultsBreast cancer-directed therapies (chemotherapy, long-term endocrine therapy, targeted therapies) can adversely impact fertility via delaying reproductive timelines and direct gonadotoxicity. Oocyte and embryo cryopreservation are first-line methods for fertility preservation; other options include ovarian tissue cryopreservation and ovarian suppression with gonadotropin-releasing hormone (GnRH) agonist administration. Pregnancy after stage 0-3 breast cancer is considered safe, with no evidence of increased recurrence or mortality risk even among those with hormonally sensitive cancers. Fertility counseling and ovarian toxicity assessment remain inconsistently implemented in clinical trials. In addition, barriers to fertility care disproportionately affect historically excluded populations.

conclusionsOncofertility is a crucial element of survivorship care for reproductive-aged patients with breast cancer. Cancer-directed therapies can significantly impair the likelihood of future fertility. Early, structured fertility counseling, multidisciplinary care team collaboration including reproductive endocrinology, and incorporation of timely fertility preservation interventions are vital to maintain fertility potential without harming oncologic outcomes. Major gaps remain in counseling practices and equitable access to fertility preservation. IMPLICATIONS FOR CANCER SURVIVORS: Enhanced access to fertility preservation, individualized reproductive planning, and multidisciplinary care teams can improve quality of life and support informed decision-making regarding future childbearing in breast cancer survivors.

Indexed as

Breast cancer survivorshipFertility preservationOncofertilityOvarian reserveOvarian toxicityReproductive counseling

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.